These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Nonalcoholic Fatty Liver Disease: Common Questions and Answers on Diagnosis and Management. Westfall E; Jeske R; Bader AR Am Fam Physician; 2020 Nov; 102(10):603-612. PubMed ID: 33179890 [TBL] [Abstract][Full Text] [Related]
27. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. Sanyal AJ; Chalasani N; Kowdley KV; McCullough A; Diehl AM; Bass NM; Neuschwander-Tetri BA; Lavine JE; Tonascia J; Unalp A; Van Natta M; Clark J; Brunt EM; Kleiner DE; Hoofnagle JH; Robuck PR; N Engl J Med; 2010 May; 362(18):1675-85. PubMed ID: 20427778 [TBL] [Abstract][Full Text] [Related]
28. [Fatty liver and raised gamma-GT: it can happen to abstainers, too]. Bischoff A MMW Fortschr Med; 2002 Feb; 144(7):18. PubMed ID: 11887726 [No Abstract] [Full Text] [Related]
29. [Non-alcoholic liver disease - diagnosis and treatment]. Sarosiekjeznach-Steinhagen A; Ostrowska J; Czerwonogrodzka-Senczyna A; Boniecka I Pol Merkur Lekarski; 2017 Nov; 43(257):237-242. PubMed ID: 29231919 [TBL] [Abstract][Full Text] [Related]
30. Improvements in Histologic Features and Diagnosis Associated With Improvement in Fibrosis in Nonalcoholic Steatohepatitis: Results From the Nonalcoholic Steatohepatitis Clinical Research Network Treatment Trials. Brunt EM; Kleiner DE; Wilson LA; Sanyal AJ; Neuschwander-Tetri BA; Hepatology; 2019 Aug; 70(2):522-531. PubMed ID: 30549292 [TBL] [Abstract][Full Text] [Related]
32. Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial. Haukeland JW; Konopski Z; Eggesbø HB; von Volkmann HL; Raschpichler G; Bjøro K; Haaland T; Løberg EM; Birkeland K Scand J Gastroenterol; 2009; 44(7):853-60. PubMed ID: 19811343 [TBL] [Abstract][Full Text] [Related]
33. Comparative therapeutic effects of metformin and vitamin E in a model of non-alcoholic steatohepatitis in the young rat. Raso GM; Esposito E; Iacono A; Pacilio M; Cuzzocrea S; Canani RB; Calignano A; Meli R Eur J Pharmacol; 2009 Feb; 604(1-3):125-31. PubMed ID: 19135440 [TBL] [Abstract][Full Text] [Related]
34. Effect of insulin-sensitizing agents in combination with ezetimibe, and valsartan in rats with non-alcoholic fatty liver disease. Assy N; Grozovski M; Bersudsky I; Szvalb S; Hussein O World J Gastroenterol; 2006 Jul; 12(27):4369-76. PubMed ID: 16865780 [TBL] [Abstract][Full Text] [Related]
35. Is vitamin e or ursodeoxycholic acid a valid treatment option for nonalcoholic fatty liver disease in 2016? Beaton MD; Al-Judaibi B Saudi J Gastroenterol; 2016; 22(3):169-70. PubMed ID: 27184632 [No Abstract] [Full Text] [Related]
36. Pharmacological treatment of non-alcoholic steatohepatitis: the current evidence. Diakou MC; Liberopoulos EN; Mikhailidis DP; Tsianos EV; Burroughs AK; Elisaf MS Scand J Gastroenterol; 2007 Feb; 42(2):139-47. PubMed ID: 17327932 [No Abstract] [Full Text] [Related]